RAC - Charts & Price Action, page-18889

@Davisite this is one of the very, very frustrating things I find about being an investor......

While it may well be wiser to hold back details of bisantrene moa in CP until IP protection is in place, at that time the market understood the details would be forthcoming, and some investors may have made buy/sell decisions in light of that expectation...

It doesn't sit well with me that the new management (of any company, not just Race) doesn't more clearly communicate that the previous managements announcements have been overturned, and the reasons why. (By the way I don't include the updated strategy in that, as I believe thats been well communicated).

Again, it may well be the right reason in this case, but the anticipated CP moa announcement has been kicked down the road, and us investors now have no idea when it will be forthcoming. Very frustrating, and the problem I have is that there is a bit of a list of these at RAC

Here's a few examples
- Ann 3/9/21, Race initiated a collaboration study to develop a genomics based companion diagnostic for Zantrene® to support its use as a precision
oncology drug (Murray Cairns study). No news
- Ann 28/6/22 - Bisantrene synergy with BRAF & MEK inhibitors in treating melanoma. Various next steps eg including research paper to be published, further preclinical studies. No paper yet published
- Ann 30/6/22 - Protects Mouse hearts from damage. Various next steps eg , incl preclincial studies on optimal dox/zan ratio,research paper to be published. No paper or conference presso
- Ann 27/9/22 - Initiate FTO & ALKBH5 Drug discovery. (Monash uni). Crickets.
- I'm sure other posters will ladd to this...

I'm not having a go at you Dr.T, I'm very glad you are the CEO, but just wanted to share from an investors perspective when announcements are made that set expectations that investors can expect further activities/news and it doesn't eventuate, well it's not good.

I guess I'm particularly sensitive to this point atm as we look to be in a dry news spell while we await updates on RC220 & the planned CP & AML trials. As we can see from the SP, the market hates a news drought.

And to conclude, despite my rant, I've still been accumulating recently....